My site

BOSTON & PERTH, Australia - Wednesday, November 7th 2012 [ME NewsWire]

Global Energy and Resources-Focused Private Equity Firm to Explore Metals and Minerals, Power and Renewables and Oil and Gas Investment Opportunities in Asia Pacific

(BUSINESS WIRE)-- Denham Capital, a leading energy and resources-focused global private equity firm, announced today that it will open an office in Perth, Australia, one of the world’s main hubs for metals and minerals activity.

The new office will open in February 2013 and be led by Bert Koth, Director of Denham Capital’s Metals and Minerals team who will be relocating from the firm’s London office. In addition to pursuing metals and minerals investments in Australia and the Asia Pacific region, the office will also seek opportunities in Denham Capital’s other two core sectors: power and renewables and oil and gas.

"While Perth and Australia are rightfully thought of as global centers for metals and minerals, investment ... Read more »

NEW YORK - Tuesday, November 6th 2012 [ME NewsWire]

• ... Read more »

SAN JOSE, Calif - Tuesday, November 6th 2012 [ME NewsWire]

Standards-Compliant Single Chip System on Chip (SoC) offers Interoperability and Best in Class Connectivity

(BUSINESS WIRE/ME NewsWire)-- EnVerv announced today general availability of its single chip EV8000 Power-Line Communication (PLC) modem System on Chip (SoC) targeted at data communication applications at the core of utility Advanced Metering Infrastructure (AMI) networks enabling reliable and extended coverage for mission critical applications such as Smart Meters, Data Concentrators, Home Energy Management Systems (HEMS), In-Home Display (IHD), etc.

"We are pleased to announce production availability of our EV8000 PLC modem to our worldwide customers,” said Shahin Hedayat, Chairman and CEO of EnVerv, adding, "Our standards compliant modem chip allows us to further expand EnVerv’s global footprint with customers deploying G3-PLC, PRIME and 4GPLC™ technologies. Furthermore, our state of the art algori ... Read more »

– Data will showcase potentially first- or best-in-class compounds –

BUSINESS WIRE / ME NewsWire DUBLIN - Tuesday, November 6th 2012

EORTC-NCI-AACR Symposium 2012

Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies. The data being presented during the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeuticsfrom November 6 – 9, 2012 in Dublin, Ireland underscore Taiho’s steadfast commitment to improving cornerstone anti-metabolic cancer agents and developing novel molecular targeted therapies that can be used alone or in combination worldwide.

"The data being presented demonstrate Taiho’s ability to develop novel molecular targeted agents as well as next generation cytotoxic therapies, and underscore our con ... Read more »

LONDON - Tuesday, November 6th 2012

(BUSINESS WIRE/ ME NewsWire)-- RIMES, the leader in index and benchmark data management, was presented with the award for ‘Best Data Provider to the Buy-Side’ for the sixth consecutive year at the Buy-Side Technology Awards ceremony held in London last week. RIMES is the only company that has won in its category since the awards began in 2007.

The Buy-Side Technology Awards recognise leading technologies and vendors in their area of expertise. The judging panel included some of the world’s leading technology consultants: Aite, Citisoft, Investit, Knadel and Parere. The full list of winners is available at: http://events.waterstechnology.com/bstawards/static/2012-winners

The award for the ‘Best Data Provider’ is given to the organisation that has displayed quality in data provision and functional services as well as the ability to easily integrate with clients systems.

Christian Fauvelais, the CEO and founder of RIMES Techn ... Read more »

INGELHEIM, Germany - Tuesday, November 6th 2012 [ME NewsWire]

- Results from real-world practice support evidence from clinical trials

- Pradaxa® is well tolerated with a good safety profile in routine clinical setting

- Benefit of Pradaxa® seen in all patients regardless of risk of bleeding and/or VTE

(BUSINESS WIRE)-- New real-world data reinforces the positive safety and efficacy profile of Pradaxa® (dabigatran etexilate) in clinical practice for the prevention of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement.* Data presented today at the 2012 American Heart Association Scientific Sessions highlight that treatment with Pradaxa® was well tolerated and resulted in low incidence of major bleeding events irrespective of patient risk factors.1

VTE has been estimated to be the third most common cardiovascular disorder after coronary heart disease and stroke.2 In Europe alone, it affects 1.5 million peop ... Read more »

Lays Foundation for Direct-to-Patient Studies Using Patient Reported Outcomes + Medical Record Methods

RESEARCH TRIANGLE PARK, N.C. - Tuesday, November 6th 2012 [ME NewsWire]

(BUSINESS WIRE)-- A new pilot study from Quintiles’ Digital Patient Unit (DPU) confirms the reliability of patient-reported outcomes collected via patients recruited over the internet, demonstrating the viability of a new method for observational research that combines patient-reported outcomes and medical record data (PRO+MR).

Findings demonstrate that patients can be recruited, screened and enrolled directly from online patient communities for observational studies that collect patient-reported-outcomes and clinical data with ~75% of physicians contributing medical record information.

A Quintiles-authored article on the PRO+MR study, "Conducting Research on the Internet: Medical Record Data Integration with Patient-Reported Outcomes,” has been published by the peer-reviewed Journal o ... Read more »

Business Wire / ME Newswire

PARIS - Tuesday, November 6th 2012

Cartes 2012

Regulatory News:

Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, won a new Sesames award at the 2012 CARTES & IDentification industry conference for its PrintPixel security feature. The winning innovation is being showcased on the Gemalto booth, Hall 3, Entrance.

"This Sesames award endorses our capacity in developing innovative products that lead to real-life applications and tangible benefits for service providers and end users, as part of our ongoing commitment to serving our customers with pioneering solutions that make them stay one step ahead,” commented Tan Teck-Lee, Gemalto’s Chief Innovation and Technology Officer. "The security features that are visible with the bare eye are always very efficient, easy to check by officials at border control and providing increased protection for citizens.”

PrintPixel™

PrintPixel is a highl ... Read more »

VIENNA - Tuesday, November 6th 2012 [ME NewsWire]

EMC Momentum 2012

(BUSINESS WIRE)-- euroscript has received this year’s EMC IIG President Award for Customer Satisfaction at EMC Momentum 2012.

For the past 25 years, euroscript has delivered top-quality services to its customers around the world, adapting to their needs, being flexible whenever required and mobilising its expertise to achieve optimum results. Since we know a satisfied customer is a loyal customer, euroscript has constantly searched for innovative approaches, developed add-ons to help customers get the best out of their technology and implemented architecture-based solutions suited to a wide range of highly specific environments.

Today, by presenting euroscript with this prestigious award, EMC recognizes euroscript’s excellence in delivering customer satisfaction and its ability to exceed customer expectations by providing the highest levels of satisfaction in terms of service and solutions.< ... Read more »

INGELHEIM, Germany - Tuesday, November 6th 2012

    New data presented at the AHA’s Scientific Sessions demonstrate antibody fragment antidote to be highly selective and specific for rapid reversal of the anticoagulant effect of dabigatran
    After successful completion of the pre-clinical research phase, Boehringer Ingelheim initiated the clinical phase I trial development of a specific antidote as a potential additional option for patient management during rare critical care situations and/or emergency surgery
    Despite the absence of a specific antidote, dabigatran proven to be highly effective for stroke prevention without increasing rate of bleeding versus warfarin

(BUSINESS WIRE/ ME NewsWire)-- For Non-US, Non-UK & Non-Canadian Media Only

New findings presented at the 2012 American Heart Association Scientific Sessions in Los Angeles provide early indications that a highly specific and selective antido ... Read more »